Home Cart Sign in  
Chemical Structure| 83881-52-1 Chemical Structure| 83881-52-1

Structure of Cetirizine 2HCl
CAS No.: 83881-52-1

Chemical Structure| 83881-52-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Cetirizine 2HCl, a metabolite of hydroxyzine, is racemic selective and inverse agonist of H1 receptor used in the treatment of allergies and hay fever.

Synonyms: P071; Cetirizine (hydrochloride); UCB-P 071

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cetirizine 2HCl

CAS No. :83881-52-1
Formula : C21H27Cl3N2O3
M.W : 461.81
SMILES Code : O=C(COCCN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(Cl)C=C3)O.[H]Cl.[H]Cl
Synonyms :
P071; Cetirizine (hydrochloride); UCB-P 071
MDL No. :MFCD00941428
InChI Key :PGLIUCLTXOYQMV-UHFFFAOYSA-N
Pubchem ID :55182

Safety of Cetirizine 2HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Cetirizine 2HCl

GPCR

Isoform Comparison

Biological Activity

Target
  • Histamine receptor

In Vitro:

Cell Line
Concentration Treated Time Description References
Murine eosinophils cultured from bone marrow 5 μM 30 minutes To measure the inhibitory effect of cetirizine on eosinophil degranulation, results showed cetirizine significantly reduced EPO release. J Clin Invest. 2013;123(5):2306-2316.
Guinea-pig ventricular myocytes 0.1 μM 10 minutes Cetirizine at 0.1 μM reduced IKr to 49%, while IKs was only inhibited to 79%. Br J Pharmacol. 1998 Jun;124(4):663-8.
Rabbit ventricular myocytes 0.1 μM 10 minutes To analyze the effect of cetirizine on delayed K+ currents, results showed cetirizine inhibited IKr current with an IC50 of 108 μM. Br J Pharmacol. 1998 Jun;124(4):663-8.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice NMO model Oral 10 mg/kg Twice daily for 3 days To study the inhibitory effect of cetirizine on NMO lesions, results showed cetirizine significantly reduced lesion severity and eosinophil infiltration. J Clin Invest. 2013;123(5):2306-2316.
Balb/C mice Ovalbumin-sensitized peritonitis model Subcutaneous injection 15-30 mg/kg 1 hour before and 6 hours after Cetirizine significantly reduced ovalbumin-induced eosinophil accumulation, whereas terfenadine was ineffective, suggesting that the effect of cetirizine was not related to the inhibition of the H1 receptor effects of histamine. Br J Pharmacol. 1993 Oct;110(2):917-24
Male Wistar rats PAF or compound 48/80-induced pleural eosinophil accumulation model Intraperitoneal or intrathoracic 5 to 30 mg/kg (i.p.) or 5 and 15 μg/cavity (i.t.) Single dose, 1 h before (i.p.) or 5 min before (i.t.) To evaluate the inhibitory effect of cetirizine on PAF or compound 48/80-induced pleural eosinophil accumulation, results showed that cetirizine significantly inhibited eosinophil accumulation, and this effect was not related to its antagonism of histamine H1 receptors. Br J Pharmacol. 1992 Jan;105(1):176-80.
Guinea-pigs Ovalbumin-sensitized paw oedema model Subcutaneous injection 20 mg/kg Single dose, measured 30 minutes after administration To evaluate the inhibitory effect of cetirizine on ovalbumin-induced paw oedema, results showed cetirizine was ineffective Br J Pharmacol. 1994 May;112(1):111-6
C57BL/6J male mice DMM-induced osteoarthritis model Oral gavage 100μg/day Once daily for 12 weeks To evaluate the effect of cetirizine on the development of osteoarthritis in the DMM mouse model. Results showed that cetirizine significantly attenuated cartilage degeneration and reduced the expression of OA-related mediator genes. Clin Immunol. 2022 Nov;244:109117
DBA/2 mice Viral myocarditis model Oral 1 or 10 mg/kg/day Once daily, starting on the day of viral inoculation Cetirizine improved survival dose dependently, significantly decreased the heart weight to body weight ratio, reduced the area of myocardial necrosis, and suppressed the gene expressions of tumor necrosis factor, interleukin 6, and metalloproteinase 2. J Inflamm (Lond). 2010 Aug 4;7:39
Guinea pigs Non-immunized guinea pigs receiving platelets from immunized animals Intravenous injection 10-30 mg/kg Administered 1 hour before antigen challenge Cetirizine dose-dependently inhibited platelet-dependent leucopenia, with the highest dose achieving complete inhibition. Terfenadine and mepyramine were ineffective. Br J Pharmacol. 1991 Jun;103(2):1520-4

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00628108 Allergic Rhinitis ... More >> Chronic Urticaria Less << Phase 3 Completed - United States, Alabama ... More >> Birmingham, Alabama, United States United States, Arkansas Hot Springs, Arkansas, United States Jonesboro, Arkansas, United States Little Rock, Arkansas, United States United States, California Bakersfield, California, United States Crescent City, California, United States Huntington Beach, California, United States Los Angeles, California, United States Orange, California, United States Roseville, California, United States Stockton, California, United States United States, Georgia Albany, Georgia, United States Gainesville, Georgia, United States United States, Illinois Normal, Illinois, United States United States, Missouri Bridgeton, Missouri, United States United States, Nebraska Omaha, Nebraska, United States United States, Oklahoma Oklahoma City, Oklahoma, United States United States, South Carolina Barnwell, South Carolina, United States Spartanburg, South Carolina, United States United States, Tennessee Kingsport, Tennessee, United States United States, Texas Austin, Texas, United States Dallas, Texas, United States El Paso, Texas, United States San Antonio, Texas, United States Sugarland, Texas, United States United States, Virginia Richmond, Virginia, United States Less <<
NCT00521131 Rhinitis Alle... More >>rgic Perennial Less << Phase 4 Completed - -
NCT00520754 Cough Phase 2 Completed - -
NCT00628108 - Completed - -
NCT00557284 Atopic Dermatitis Phase 4 Completed - United States, Colorado ... More >> 1st Allergy & Clinical Research Centers Centennial, Colorado, United States, 80112 1st Allergy & Clinical Research Centers Thornton, Colorado, United States, 80229 Less <<
NCT01567501 Fed Phase 1 Completed - India ... More >> Accutest Research Lab (I) Pvt. Ltd. Ahmedabad, Gujarat, India, 380054 Less <<
NCT01557439 Fasting State Phase 1 Completed - India ... More >> Accutest Research Lab (I) Pvt. Ltd. Ahmedabad, Gujarat, India, 380054 Less <<
NCT00557284 - Completed - -
NCT02583594 Progressive Multiple Sclerosis Phase 1 Active, not recruiting April 2021 Spain ... More >> Investigational Site Number 724001 Barcelona, Spain, 08035 Less <<
NCT03590912 Otitis Media With Effusion Phase 4 Not yet recruiting September 2019 Nepal ... More >> Lumbini Medical College Tansen, Palpa, Nepal, 32500 Less <<
NCT00001910 - Completed - United States, Maryland ... More >> National Institute of Allergy and Infectious Diseases (NIAID) Bethesda, Maryland, United States, 20892 Less <<
NCT02771249 Healthy Volunteers Phase 1 Recruiting December 31, 2019 United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010    prpl@cc.nih.gov Less <<
NCT03523221 Mild -Moderate Anaphylaxis - S... More >>ymptoms That Affect the Skin With Cardiovascular, Respiratory or Gastrointestinal Involvement, But no Signs of Hypotension ,Laryng Less << Phase 1 Recruiting August 2020 Qatar ... More >> Hamad Medical Corporation Recruiting Doha, Qatar, 3050 Contact: Rafah Sayyed, MD    +97455747045    ralsayyed@hamad.qa Less <<
NCT02646904 Allergic Rhinitis Phase 4 Completed - Italy ... More >> Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council Palermo, Sicily, Italy, 90146 Institute of Biomedicine and Molecular Immunology, IBIM Palermo, Italy, 90146 Less <<
NCT03296358 Urticaria All... More >>ergy Less << Not Applicable Recruiting October 31, 2019 Thailand ... More >> Chulalongkorn Hospital Recruiting Pathum Wan, Bangkok, Thailand, 10600 Contact: Pakhawadee Palungwachira, Bachelor    66897704758    zaphyr_s@yahoo.com    Principal Investigator: Pakhawadee Palungwachira, Bachelor          Sub-Investigator: Katsara Vilaisri, Bachelor          Sub-Investigator: Klongwong Musikatavorn, Bachelor Less <<
NCT02873364 Urticaria Phase 3 Unknown January 2017 Iran, Islamic Republic of ... More >> Shiraz University of Medical Sciences Recruiting Shiraz, Fars, Iran, Islamic Republic of Contact: Keramatallah Jahanshahi, MD    +989177416523    kjahanshahi91@gmail.com Less <<
NCT00561717 Seasonal Allergic Rhinitis Phase 4 Completed - Canada, Ontario ... More >> Kingston, Ontario, Canada, K7L 2V7 Less <<
NCT02613910 - Terminated(Novartis has acquir... More >>ed the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration.) Less << - -
NCT01241214 Seasonal Allergic Rhinitis Phase 2 Completed - United States, Texas ... More >> Clinical Investigative Site 7905 Austin, Texas, United States, 78731 Clinical Investigative Site 7907 Kerrville, Texas, United States, 78028 Clinical Investigative Site 7903 New Braunfels, Texas, United States, 78130 Clinical Investigative Site 7901 San Antonio, Texas, United States, 78229 Clinical Investigative Site 7902 San Antonio, Texas, United States, 78229 Clinical Investigative Site 7904 San Antonio, Texas, United States, 78229 Clinical Investigative Site 7906 San Antonio, Texas, United States, 78229 Less <<
NCT01451996 Healthy Phase 4 Completed - United States, Illinois ... More >> University of Chicago Chicago, Illinois, United States, 60637 Less <<
NCT02613910 Pemphigus Phase 3 Terminated(Novartis has acquir... More >>ed the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration.) Less << - United States, California ... More >> GSK Investigational Site Los Angeles, California, United States, 90045 United States, Michigan GSK Investigational Site Ann Arbor, Michigan, United States, 48103 Less <<
NCT01451996 - Completed - -
NCT01985789 Asthma Phase 4 Completed - Canada, Saskatchewan ... More >> University of Saskatchewan Saskatoon, Saskatchewan, Canada, S7N 0W8 Less <<
NCT01940393 Urticaria Phase 4 Completed - Colombia ... More >> Medellin Medellin, Antioquia, Colombia Less <<
NCT01134328 Allergic Conjunctivitis Phase 2 Completed - United States, Massachusetts ... More >> Ora, Inc Andover, Massachusetts, United States, 01810 Less <<
NCT01902836 Childhood Atopic Dermatitis Phase 2 Completed - Mexico ... More >> Hospital Infantil de México, Fedérico Gómez México, DF, Mexico, 06720 Less <<
NCT01981499 Migraine Phase 1 Terminated(The trial was prema... More >>turely terminated on 01April2014 due to safety concerns.) Less << - United States, Minnesota ... More >> Pfizer Investigational Site St. Paul, Minnesota, United States, 55114 Less <<
NCT01134328 - Completed - -
NCT02535416 Healthy Phase 1 Completed - Australia, Queensland ... More >> QPharm, Pty Limited, Royal Brisbane Hospital Herston, Queensland, Australia, 4029 Less <<
NCT00517946 - Completed - United Kingdom ... More >> GSK Investigational Site London, United Kingdom, W1G 8HU Less <<
NCT02535416 - Completed - -
NCT02024152 Acute Urticaria Phase 1 Completed - Canada, Quebec ... More >> Algorithme Pharma Montreal, Quebec, Canada Less <<
NCT01008592 - Terminated(Mediators of intere... More >>st were not consistently detectable with the analytical methods employed.) Less << - United States, North Carolina ... More >> Wake Forest University Health Sciences, Department of Dermatology Winston-Salem, North Carolina, United States, 27157 Less <<
NCT01318681 Seasonal Allergic Rhinitis ... More >> Driving Ability Cognition Less << Not Applicable Completed - Netherlands ... More >> Maastricht University Maastricht, Limburg, Netherlands, 62ooMD Less <<
NCT00533637 Allergic Rhinitis Phase 2 Completed - Sweden ... More >> Department of Otorhinolaryngology, Lund University Hospital Lund, Sweden, SE-221 85 Less <<
NCT01068223 Histamine Induced Itch Phase 1 Completed - United Kingdom ... More >> Harrow, United Kingdom Less <<
NCT01484119 Seasonal Allergic Rhinitis Phase 3 Completed - United States, Texas ... More >> Clinical Investigative Site 7905 Austin, Texas, United States, 78731 Clinical Investigative Site 7907 Kerrville, Texas, United States, 78028 Clinical Investigative Site 7903 New Braunfels, Texas, United States, 78130 Clinical Investigative Site 7901 San Antonio, Texas, United States, 78229 Clinical Investigative Site 7902 San Antonio, Texas, United States, 78229 Clinical Investigative Site 7904 San Antonio, Texas, United States, 78229 Clinical Investigative Site 7906 San Antonio, Texas, United States, 78229 Less <<
NCT02451579 Actinic Keratoses Not Applicable Completed - United States, California ... More >> Cosmetic Laser Dermatology San Diego, California, United States, 92121 Less <<
NCT02935699 Acute Urticaria Phase 3 Recruiting April 2018 United States, Texas ... More >> City Doc Urgent Care center Recruiting Dallas, Texas, United States, 75209 Contact: Brook Jackson          Canada, Ontario Ottawa Hospital Recruiting Ottawa, Ontario, Canada, K1Y 4E9 Contact: Cathy Clement Less <<
NCT00974571 - Completed - -
NCT00610584 Seasonal Allergic Rhinitis Not Applicable Completed - Germany ... More >> Charité - Institute for Social Medicine Berlin, Germany, 10098 Less <<
NCT00291642 Rhinitis Alle... More >>rgic Seasonal Less << Phase 2 Completed - Canada, Ontario ... More >> Kingston, Ontario, Canada Less <<
NCT00851344 Rhinitis, Allergic, Seasonal Phase 2 Completed - Germany ... More >> GSK Investigational Site Hannover, Niedersachsen, Germany, 30625 Less <<
NCT03167216 Chronic Prostatitis With Chron... More >>ic Pelvic Pain Syndrome Less << Early Phase 1 Recruiting June 30, 2021 United States, Illinois ... More >> Northwestern Medical Faculty Foundation Recruiting Chicago, Illinois, United States, 60611 Principal Investigator: Praveen Thumbikat, PhD Less <<
NCT00974571 Perennial Allergic Rhinitis Phase 3 Completed - -
NCT01825655 Pruritus Phase 4 Terminated(Unable to recruit p... More >>atients) Less << - United States, Virginia ... More >> Children's Hospital of Richmond at VCU Richmond, Virginia, United States, 23298 Less <<
NCT01825655 - Terminated(Unable to recruit p... More >>atients) Less << - -
NCT00544388 Rhinitis, Allergic, Seasonal Phase 3 Completed - -
NCT02447393 Dermatitis Phase 1 Completed - Japan ... More >> GSK Investigational Site Kagoshima, Japan, 890-0081 Less <<
NCT00291642 - Completed - -
NCT00972504 Rhinitis, Allergic, Seasonal Phase 2 Completed - Germany ... More >> GSK Investigational Site Hannover, Niedersachsen, Germany, 30625 Less <<
NCT01495338 Normal Ocular Health Phase 1 Completed - United States, Massachusetts ... More >> Andover Eye Associates Andover, Massachusetts, United States, 01810 Less <<
NCT00474890 Atopy Rhiniti... More >>s Less << Not Applicable Completed - Germany ... More >> Fraunhofer Institute for Toxicology and Experimental Medicine Hannover, Germany, 30625 Less <<
NCT00257595 Rhinitis, Allergic, Perennial Phase 3 Completed - -
NCT01322282 Allergy Phase 1 Completed - Canada, Quebec ... More >> Algorithme Pharma Inc. Mount-Royal, Quebec, Canada, H3P 3P1 Less <<
NCT00420082 Seasonal Allergic Rhinitis Phase 2 Completed - Austria ... More >> Allergy Center Vienna West Vienna, Austria, A-1150 Less <<
NCT00972504 - Completed - -
NCT03192488 Exercise Intolerance at Altitu... More >>de Less << Phase 4 Recruiting May 31, 2018 United States, Indiana ... More >> Indiana University Recruiting Bloomington, Indiana, United States, 47401 Contact: Robert Chapman, PhD    812-856-2452    rfchapma@indiana.edu Less <<
NCT01651871 Seasonal Allergic Rhinitis Phase 2 Completed - -
NCT00334698 Seasonal Allergic Rhinitis Not Applicable Completed - Germany ... More >> Fraunhofer-Institute of Toxicology and Experimental Medicine Hannover, Germany, 30623 Less <<
NCT01103050 Allergic Rhinitis Phase 2 Completed - Canada ... More >> Novartis Investigative Site Ontario, Canada Less <<
NCT00257569 Dermatitis, Atopic Phase 3 Completed - -
NCT02543346 Allergic Rhinitis Phase 4 Completed - United States, Texas ... More >> Biogenics Research Chamber San Antonio, Texas, United States, 78229 Canada, Ontario Kingston General Hospital Kingston, Ontario, Canada, K7L 2V7 Less <<
NCT03047278 Neuropathic Pain ... More >> Type 2 Diabetes Mellitus Diabetic Neuropathy, Painful Less << Phase 4 Enrolling by invitation July 1, 2019 -
NCT01748344 Seasonal Allergic Rhinitis Phase 2 Completed - Austria ... More >> Vienna Clinical Site Vienna, Austria Less <<
NCT00253058 Rhinitis, Allergic, Perennial Phase 3 Completed - -
NCT00751218 Urticaria Phase 4 Completed - -
NCT00751166 Urticaria Phase 4 Terminated(Study could not be ... More >>re-supplied with study medication in a timely manner.) Less << - -
NCT00504933 Seasonal Allergic Rhinitis Phase 3 Completed - -
NCT01127620 Perennial Allergic Rhinitis Phase 3 Completed - -
NCT00637455 Seasonal Allergic Rhinitis Phase 4 Completed - United States, New Jersey ... More >> Sanofi-Aventis Bridgewater, New Jersey, United States, 08807 Less <<
NCT00240032 Multiple Sclerosis Phase 4 Completed - -
NCT01622283 Rhinitis, Allergic, Perennial ... More >>and Seasonal Less << Phase 1 Completed - Japan ... More >> GSK Investigational Site Kagoshima, Japan, 890-0081 Less <<
NCT00881634 Allergies Phase 1 Completed - -
NCT00257582 Pruritus Phase 3 Completed - -
NCT00150761 Anti-allergic Agents Phase 4 Completed - -
NCT00488176 Seasonal Allergic Rhinitis Phase 4 Unknown December 2013 Poland ... More >> Department of Pediatrics and Allergy, Medical University of Lodz Lodz, Poland Recruiting Lodz, Poland, 93-513 Contact: Violetta Ścibiorek, MD    00 48 42 689 59 72    alergol@kopernik.lodz.pl    Principal Investigator: Iwona Stelmach, MD, PhD, Prof Less <<
NCT00650065 Healthy Phase 1 Completed - United States, Texas ... More >> Novum Pharmaceutical Research Services Houston, Texas, United States, 77042 Less <<
NCT00826943 Allergic Rhinitis Phase 4 Completed - United States, Tennessee ... More >> Vanderbilt University Asthma, Sinus, and Allergy Clinic Nashville, Tennessee, United States, 37203 Less <<
NCT00826943 - Completed - -
NCT00881127 Allergies Phase 1 Completed - -
NCT01551056 Allergic Conjunctivitis Phase 3 Completed - United States, Massachusetts ... More >> Ora, Inc. Andover, Massachusetts, United States, 01810 Less <<
NCT02173249 Healthy Phase 1 Completed - United States, Massachusetts ... More >> Andover Eye Associates Andover, Massachusetts, United States, 01810 Less <<
NCT01551056 - Completed - -
NCT01685242 Allergic Conjunctivitis Phase 3 Completed - United States, Massachusetts ... More >> Andover Eye Associates Andover, Massachusetts, United States, 01810 Less <<
NCT01685242 - Completed - -
NCT01881113 Allergic Conjunctivitis Phase 3 Completed - United States, Massachusetts ... More >> Ora, Inc. Andover, Massachusetts, United States, 01810 Less <<
NCT00639587 Rhinitis, Allergic, Perennial Phase 3 Completed - -
NCT01916226 Rhinitis, Allergic, Perennial ... More >>and Seasonal Less << Phase 4 Completed - -
NCT00375713 Dermatitis Ec... More >>zema Less << Phase 3 Completed - Korea, Republic of ... More >> Gyeunggi-do, Korea, Republic of Kyeonggi-Do, Korea, Republic of Seoul, Korea, Republic of Less <<
NCT01881113 - Completed - -
NCT00375713 - Completed - -
NCT02756624 Healthy Subjects Phase 3 Completed - United States, Massachusetts ... More >> Ora Clinical Site Network Andover, Massachusetts, United States, 01810 Less <<
NCT00490204 Rhinitis, Allergic, Perennial Phase 3 Completed - Japan ... More >> GSK Investigational Site Chiba, Japan, 277-0882 GSK Investigational Site Fukuoka, Japan, 807-0856 GSK Investigational Site Fukuoka, Japan, 811-1201 GSK Investigational Site Fukuoka, Japan, 819-0002 GSK Investigational Site Hokkaido, Japan, 001-0923 GSK Investigational Site Hokkaido, Japan, 007-0840 GSK Investigational Site Hokkaido, Japan, 053-0833 GSK Investigational Site Hokkaido, Japan, 061-1133 GSK Investigational Site Hokkaido, Japan, 061-1448 GSK Investigational Site Hokkaido, Japan, 062-0034 GSK Investigational Site Kanagawa, Japan, 212-0027 GSK Investigational Site Kanagawa, Japan, 213-0011 GSK Investigational Site Kanagawa, Japan, 216-0002 GSK Investigational Site Kanagawa, Japan, 222-0011 GSK Investigational Site Kanagawa, Japan, 224-0003 GSK Investigational Site Kanagawa, Japan, 232-0056 GSK Investigational Site Kumamoto, Japan, 862-0952 GSK Investigational Site Kumamoto, Japan, 862-0962 GSK Investigational Site Oita, Japan, 870-0021 GSK Investigational Site Saitama, Japan, 333-0861 GSK Investigational Site Saitama, Japan, 336-0022 GSK Investigational Site Saitama, Japan, 350-1205 GSK Investigational Site Saitama, Japan, 355-0062 GSK Investigational Site Shizuoka, Japan, 420-0803 GSK Investigational Site Shizuoka, Japan, 422-8066 GSK Investigational Site Shizuoka, Japan, 436-0058 GSK Investigational Site Tokyo, Japan, 157-0067 GSK Investigational Site Tokyo, Japan, 170-0005 Less <<
NCT02756624 - Completed - -
NCT01332188 Allergic Conjunctivitis Phase 2 Phase 3 Completed - United States, Massachusetts ... More >> Ora, Inc. Andover, Massachusetts, United States, 01810 Less <<
NCT00649857 Healthy Phase 1 Completed - United States, Texas ... More >> Novum Pharmaceutical Research Services Houston, Texas, United States, 77042 Less <<
NCT01916226 - Completed - -
NCT01332188 - Completed - -
NCT00794378 Allergic Rhinitis Phase 3 Completed - -
NCT00779116 - Completed - -
NCT02932774 Allergic Rhinitis ... More >> Hay Fever SAR Rhinitis, Allergic, Seasonal Less << Phase 4 Completed - -
NCT03340740 Allergic Rhinitis ... More >> Asthma Less << Phase 4 Recruiting December 31, 2018 United States, New York ... More >> Jacobi Medical Center Recruiting Bronx, New York, United States, 10461 Contact: Stephen Blumberg, MD    718-918-5826    stephen.blumberg@nychhc.org    Contact: Katherine Huston, MD    718-918-5875    hustonk@nychhc.org Less <<
NCT00779116 Allergies Phase 4 Completed - -
NCT00794794 Allergic Rhinitis Phase 3 Completed - -
NCT00780403 - Completed - -
NCT00780403 Allergies Phase 4 Completed - -
NCT00776139 Healthy Not Applicable Completed - United States, Maryland ... More >> Bioanalytical Systems, Inc. Baltimore, Maryland, United States, 21201 Less <<
NCT00794495 Seasonal Allergic Rhinitis ... More >> Perennial Allergic Rhinitis Less << Phase 4 Completed - -
NCT00776022 Healthy Not Applicable Completed - United States, Maryland ... More >> Bioanalytical Systems, Inc Baltimore, Maryland, United States, 21201 Less <<
NCT00794599 Seasonal Allergic Rhinitis ... More >> Perennial Allergic Rhinitis Less << Phase 4 Completed - -
NCT00863902 Healthy Phase 1 Completed - United States, North Carolina ... More >> AAIPharma Inc.- AAI Clinic Morrisville, North Carolina, United States, 27560 Less <<
NCT02132169 Atopic Disease (Including Alle... More >>rgic Conjunctivitis) Less << Phase 3 Completed - United States, Massachusetts ... More >> Ora, Inc. Andover, Massachusetts, United States, 01810 Less <<
NCT02132169 - Completed - -
NCT01781507 Allergic Rhinitis ... More >> Asthma Less << Phase 4 Completed - United States, California ... More >> California Allergy and Asthma Medical Group Los Angeles, California, United States, 90025 Less <<
NCT03772158 Allergy Phase 1 Recruiting February 3, 2019 Canada, Quebec ... More >> Algorithme (An altascience Company) Recruiting Mount-Royal, Quebec, Canada, H3P 3P1 Contact: Bich-Chau Le    +1 (514) 858-6077 ext ext. 3236    Bich-Chau@altasciences.com    Principal Investigator: Eric Sicard, MD Less <<
NCT01064115 Healthy Phase 1 Completed - -
NCT02865018 Neuromyelitis Optica Phase 1 Phase 2 Completed - United States, New York ... More >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Less <<
NCT00864279 Healthy Phase 1 Completed - United States, North Carolina ... More >> AAIPharma Inc.- AAI Clinic Morrisville, North Carolina, United States, 27560 Less <<
NCT00794846 Seasonal Allergic Rhinitis ... More >> Perennial Allergic Rhinitis Less << Phase 4 Completed - -
NCT01064102 Healthy Phase 1 Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.17mL

0.43mL

0.22mL

10.83mL

2.17mL

1.08mL

21.65mL

4.33mL

2.17mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories